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gation of this regimen for unﬁt patients, with reduced vinorelbine dose 
of 20 mg/m2 aiming at lower hematological toxicity.
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Background: Single-agent chemotherapy (gemcitabine or vinorel-
bine) is currently the standard treatment for elderly advanced NSCLC 
patients. The combination of gemcitabine+docetaxel was active but not 
well tolerated in this subset (Hainsworth et al, Clin Lung Cancer 2003). 
Modiﬁed schedule of docetaxel (37.5 mg/m2 on day 1 and 8 every 3 
weeks) is active and well tolerated in pre-treated elderly advanced 
NSCLC patients (Tibaldi et al, Clin Lung Cancer, 2006). Aim of this 
study was to evaluate the activity and the toxicity of a sequential regi-
men of gemcitabine followed by docetaxel in elderly advanced NSCLC 
patients.
Methods: Chemo-naïve elderly patients (> 70 years old) with histolog-
ically or cytologically conﬁrmed stage IIIB (positive pleural effusion or 
metastatic supraclavear lymph nodes) or IV NSCLC and a performance 
status (PS) 0-2 were treated with gemcitabine 1200 mg/m2 on Day 1 
and 8 every 3 weeks for 3 cycles followed by, in case of no progres-
sive disease, docetaxel 37.5 mg/m2 on Day 1 and 8 every 3 weeks for 
further 3 cycles. 
Results: Fifty-six patients were enrolled into the study: 46 male and 10 
women; 13 stage IIIB and 43 stage IV; 7 PS 0, 38 PS1, 11 PS2; median 
age was 75 years (range 70-84). The median number of major comor-
bidities was 2.
All the patients were evaluable for toxicity and 45 were evaluable for 
response. Toxicity was mild; afebrile grade 3-4 neutropenia was ob-
served in 4 patients (7.1%) and grade 3 thrombocytopenia in 2 patients 
(3.6%); no grade 3-4 anaemia was observed. Non-haematological grade 
3-4 toxicities were: fatigue in 5 patients (8.9%), diarrhoea in 1 patient 
(1.8%) and mucositis in 2 patients (3.6%). Nine of the 45 evaluable pa-
tients showed a partial response (20%, 95% CI 9.6% - 34.6%), 17 had a 
stable disease (37.8%) and 19 a progression (42.2%). Five patients had 
a conversion from stable disease to partial response by docetaxel. 
Conclusion: Sequential chemotherapy with gemcitabine and docetaxel 
seems active and well tolerated in elderly advanced NSCLC patients. 
The ﬁnal analysis will be presented at the meeting.
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Objectives: The aim of the present study is to evaluate the efﬁcacy and 
toxicity of weekly docetaxel combined with cisplatin as ﬁrst-line che-
motherapy in patients with locally advanced or metastatic NSCLC and 
to identify the optimal dose of weekly docetaxel to be administered.
Methods: Chemonaive patients over 18 years of age with NSCLC 
stage IIIB and malignant pleural effusion, or stage IV were enrolled in 
this study. In the dose ﬁnding portion, patients received docetaxel once 
weekly at an initial dose of 25 mg/m2 for three weeks with cisplatin 
added on day 15 at a ﬁxed dose of 75 mg/m2. The dose of docetaxel 
was escalated by 3 mg/m2 for each level to a maximum dose of 34 
mg/m2. Treatment was repeated every 4 weeks for 6 cycles unless 
progressive disease, unacceptable toxicity, or consent withdrawal were 
present. Patients were enrolled in cohorts of 3 to receive combination 
chemotherapy. If a dose-limiting toxicity (DLT) occurred in 1 of the 
3 patients, 3 additional patients would be enrolled at that dose level. 
DLT was deﬁned as any grade 3-4 non-hematological toxicity (except 
alopecia, nausea and vomiting), grade 4 hematologic toxicity, or grade 
3 hematologic toxicity with complications (e.g. neutropenic fever or 
bleeding). The maximum-tolerated dose (MTD) was deﬁned as the 
dose immediately below the level associated with the occurrence of 
DLT in more than one-third of treated patients. 
Results: Forty-nine patients were enrolled into this phase I/II study. In 
the dose-ﬁnding portion, the MTD of docetaxel was not reached since 
no patient developed DLT when docetaxel was given at the highest 
dose of 34 mg/m2. In the phase II portion, 18 patients received docetax-
el at 34 mg/m2 and 14 patients received 31 mg/m2. Of the 49 eligible 
patients, none had a complete response and 19 achieved a partial 
response. The overall response rate was 38.8% (95% CI: 26.7-55.6%). 
Twenty-one patients (42.9%) had stable disease. The median survival 
was 13.1 months (95% CI: 10.4 - 15.6 months). Only 2 patients (4.1%) 
developed grade 3/4 neutropenia and there was no febrile neutropenia. 
The major non-hematological toxicities were asthenia and peripheral 
neuropathy, but most of them were grade 1 or 2.
Conclusions: Weekly docetaxel combined with cisplatin on day 15 has 
an acceptable toxicity proﬁle and is an effective regimen as ﬁrst-line 
chemotherapy in NSCLC. No dose-limiting toxicities were observed 
even when weekly docetaxel was given at 34 mg/m2.
